MannKind Corporation (MNKD)
| Market Cap | 1.22B -2.1% |
| Revenue (ttm) | 360.78M +21.2% |
| Net Income | -23.91M |
| EPS | -0.09 |
| Shares Out | 308.95M |
| PE Ratio | n/a |
| Forward PE | 131.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,325,676 |
| Open | 4.210 |
| Previous Close | 4.130 |
| Day's Range | 3.950 - 4.235 |
| 52-Week Range | 2.230 - 6.510 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 7.59 (+92.15%) |
| Earnings Date | Aug 7, 2026 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in... [Read more]
Financial Performance
In 2025, MannKind's revenue was $348.97 million, an increase of 22.23% compared to the previous year's $285.50 million. Earnings were $5.86 million, a decrease of -78.75%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MNKD stock is "Strong Buy." The 12-month stock price target is $7.59, which is an increase of 92.15% from the latest price.
News
MannKind Transcript: FDA announcement
FDA approved FUROSCIX ReadyFlow, a rapid auto-injector for IV-equivalent furosemide, enabling at-home treatment for fluid overload. Clinical studies confirmed bioequivalence and safety, with launch activities and real-world evidence generation underway. Major cost savings and broad adoption are anticipated.
MannKind Press release: FDA announcement
MannKind issued a press release on July 24, 2026, disclosing material business information to investors.
MannKind announces FDA approval of Furoscix ReadyFlow
MannKind (MNKD) announced that the U.S. FDA has approved Furoscix ReadyFlow for the treatment of edema in adults with heart failure or chronic kidney disease. Furoscix ReadyFlow is an at-home…
MannKind announces $50M private placement
MannKind (MNKD) announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors. The gross proceeds from the private placem...
MannKind Announces $50 Million Private Placement
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema
MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright
H.C. Wainwright views the July 26 FDA action date for the Furoscix ReadyFlow Autoinjector as an “underappreciated catalyst” for MannKind (MNKD) shares. Approval could materially improve the growth and...
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
MannKind Transcript: Jefferies Global Healthcare Conference 2026
Recent pediatric approval for Afrezza is expected to drive significant growth, with early launch signals showing strong demand and a compounding effect as children transition to adult care. FUROSCIX is on track for auto-injector approval, supporting robust revenue guidance, while the pipeline advances with inhaled nintedanib and other programs.
MannKind announces milestones in development of nintedanib DPI for IPF
MannKind (MNKD) announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis, or IPF, including the completion of patient randomization in the U.S...
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
MannKind price target raised to $11 from $10 at Wells Fargo
Wells Fargo raised the firm’s price target on MannKind (MNKD) to $11 from $10 and keeps an Overweight rating on the shares. The firm cites Afrezza’s approval in pediatric patients…
MannKind Transcript: FDA announcement
Afrezza received FDA approval for pediatric use in patients six and older, offering the first inhaled mealtime insulin alternative to injections. Clinical trials showed non-inferior efficacy, stable lung function, and improved satisfaction. Launch efforts focus on education, access, and rapid adoption.
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA ...
US FDA approves MannKind's inhaled insulin for children
The U.S. Food and Drug Administration has approved expanded use of MannKind's inhaled rapid-acting insulin in children with diabetes, offering patients under 18 years of age a needle-free treatment...
MannKind announces FDA approval of Afrezza for use in children aged 6 and older
MannKind (MNKD) announced that the U.S. Food and Drug Administration has approved Afrezza Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and…
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes
MannKind to Present at Jefferies Global Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participa...
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS
MannKind Transcript: AGM 2026
The meeting confirmed a quorum, elected nine directors, and approved executive compensation and auditor ratification. Strategic updates included major product launches, pipeline progress, and revenue growth projections, with Q&A addressing diversification and partnership strategies.
MannKind price target lowered to $7 from $8 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on MannKind (MNKD) to $7 from $8 and keeps an Outperform rating on the shares.
MannKind price target raised to $10 from $8 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps a Buy rating on the shares. MannKind’s Q1 results missed estimates but this does…
MannKind price target raised to $10 from $8 at Wells Fargo
Wells Fargo raised the firm’s price target on MannKind (MNKD) to $10 from $8 and keeps an Overweight rating on the shares following the disclosure of the company’s involvement with…
MannKind reports Q1 EPS (2c), consensus 1c
Reports Q1 revenue $90.17M, consensus $105.31M. “We are making meaningful progress executing our corporate transformation strategy, focused on the expansion and diversification of both our commercial ...